Table 1.

Eligibility criteria, according to hospital admission status at time of enrolment

Criteria	Inpatients (India and Australia)	Virtual care patients (Australia only)
Inclusion
Laboratory-confirmed active SARS-CoV-2 infection within 10 days prior to randomisation, using any locally approved testing method	✓	✓
Aged ≥ 18 years	✓	✓
Be at high risk of severe disease, defined as:
• Requiring hospital admission for the management of COVID-19 or,	✓	❌
• Having at least one of the following risk factors for severe disease: - Aged ≥ 60 years - BMI ≥ 30 kg/m2 - Diagnosis of diabetes defined as HbA1c ≥7% and/or use of glucose-lowering medication - History of cardiovascular diseasea - History of chronic respiratory diseasea - Current treatment with immunosuppression	±	✓
SBP ≥ 120 mmHg, or SBP ≥ 115 mmHg and receiving treatment with a non-RAAS-inhibitor blood pressure-lowering agent that can be ceased	✓	✓
Willing and able to perform trial procedures	✓	✓
Exclusion
Reduced eGFR in preceding 3 months, defined as < 30 mL/min/1.73m2 or the absence of an eGFR test	✓	❌
Reduced eGFR in preceding three months, defined as < 45 mL/min/1.73m2 or the absence of an eGFR test	❌	✓
Elevated serum potassium, defined as > 5.2 mmol/L, within the preceding 3 months or the absence of a serum potassium test	✓	✓
Receiving treatment with an ACE inhibitor, ARB, aldosterone antagonist, aliskiren or angiotensin receptor neprilysin inhibitor	✓	✓
Known intolerance to ARBs	✓	✓
Known symptomatic postural hypotension	✓	✓
Known biliary obstruction or severe hepatic impairment	✓	✓
Inability to take medications by mouth during the first 48 h after randomisation	✓	✓
Women who are currently pregnant or breast feeding (India) Or Women < 51 years without a negative pregnancy test during the previous 3 days and/or who do not agree to use adequate contraception during the 28-day treatment period (Australia)	✓	✓

^aAs defined by the treating clinician